. To identify subset-specific regulators of DCs, we developed a systems biology tool called data-driven network-based Bayesian inference of drivers (NetBID), by integrating data from transcriptomics, whole proteomics and phosphoproteomics (Fig. 1a) . Specifically, we computationally reconstructed a DC-specific signalling interactome (DCI) from a collective cohort of transcriptomic profiles of total DCs (Extended Data Fig. 1a ) using information theory-based approaches 6,7 . Next, we superimposed the DCI with the transcriptome, proteome and phosphoproteome of CD8α + and CD8α − DCs. We hypothesized that if a signalling protein is a unique driver between DC subsets, its regulons in the DCI should be enriched in the differentially expressed genes and proteins, although the driver itself is not necessarily differentially expressed. Given their crucial roles in immune function 8 , we focused on protein kinases and identified 36 hub kinases whose regulons in the DCI were enriched in CD8α + versus CD8α − DC signatures in all of the transcriptome, proteome and phosphoproteome profiles (Extended Data Fig. 1b, c) . There was a striking enrichment of Hippo signalling 9 (Extended Data Fig. 1b, d ), as many kinases involved in Hippo signalling (Extended Data Fig. 1e) were identified by NetBID, including Mst1 (also known as Stk4). Immunoblot analysis showed that CD8α + DCs had increased phosphorylation of Mst1/2 and Yap, and increased expression of Lats1 in comparison to CD8α − DCs (Fig. 1b) . Moreover, the predicted regulons of Mst1 (Extended Data Fig. 1f) were considerably dysregulated upon deletion of Mst1/2 in total, CD8α + and CD8α − DCs (Fig. 1c and Extended Data Fig. 1g, h Fig. 2c ), which was associated with a reduced effector/memory T cell population (Fig. 1d, Extended Data Fig. 2d ), but CD4 + T cell homeostasis was largely unperturbed. Furthermore, CD44 high CD8
. To identify subset-specific regulators of DCs, we developed a systems biology tool called data-driven network-based Bayesian inference of drivers (NetBID), by integrating data from transcriptomics, whole proteomics and phosphoproteomics (Fig. 1a) . Specifically, we computationally reconstructed a DC-specific signalling interactome (DCI) from a collective cohort of transcriptomic profiles of total DCs (Extended Data Fig. 1a ) using information theory-based approaches 6, 7 . Next, we superimposed the DCI with the transcriptome, proteome and phosphoproteome of CD8α + and CD8α − DCs. We hypothesized that if a signalling protein is a unique driver between DC subsets, its regulons in the DCI should be enriched in the differentially expressed genes and proteins, although the driver itself is not necessarily differentially expressed. Given their crucial roles in immune function 8 , we focused on protein kinases and identified 36 hub kinases whose regulons in the DCI were enriched in CD8α + versus CD8α − DC signatures in all of the transcriptome, proteome and phosphoproteome profiles (Extended Data Fig. 1b, c ). There was a striking enrichment of Hippo signalling 9 (Extended Data Fig. 1b, d ), as many kinases involved in Hippo signalling (Extended Data Fig. 1e ) were identified by NetBID, including Mst1 (also known as Stk4). Immunoblot analysis showed that CD8α + DCs had increased phosphorylation of Mst1/2 and Yap, and increased expression of Lats1 in comparison to CD8α
− DCs (Fig. 1b) . Moreover, the predicted regulons of Mst1 (Extended Data Fig. 1f ) were considerably dysregulated upon deletion of Mst1/2 in total, CD8α + and CD8α
− DCs ( Fig. 1c and Extended Data Fig. 1g , h). Using this unbiased approach to capture putative master regulators, we have identified the marked enrichment of Hippo signalling in CD8α + DCs. To systemically dissect the Hippo pathway in DCs, we engineered DC-specific deletion of Mst1/2, Lats1/2 or Yap/Taz using CD11c-Cre mice, resulting in Mst1/2 
CD8
+ T cells from Mst1/2 ΔDC mice expressed less IFNγ, while CD44 high CD4 + T cells had slightly reduced IFNγ but normal IL-2, IL-4 and IL-17A expression (Fig. 1e, Extended Data Fig. 2e ). In contrast to Mst1/2 ΔDC mice, Lats1/2 ΔDC and Yap/Taz ΔDC mice exhibited normal T cell homeostasis (Extended Data Fig. 2f-k) . Also, deletion of Mst1 or Mst2 alone did not affect immune homeostasis (Extended Data Fig. 2l-n) . We verified the specific loss of Mst1/2 expression in DCs from Mst1/2 ΔDC mice (Extended Data Fig. 3a, b) and rescue of CD8 + T cell phenotypes in mixed bone marrow chimaeras comprised of wild-type and Mst1/2 ΔDC bone marrow-derived cells (Extended Data Fig. 3c, d ). These results show that DCs require Mst1/2 to selectively orchestrate CD8 + T cell homeostasis, and this occurs independently of the classical Hippo pathway.
After challenge with MC38 colon adenocarcinoma cells, Mst1/2 ΔDC mice exhibited drastically increased tumour growth (Fig. 1f) and impaired IFNγ expression in CD8 + T cells (Extended Data Fig. 4a, b ), although expression of PD-1, LAG3 and TIM3 were unaltered (Extended Data Fig. 4c, d ). Additionally, Mst1/2 ΔDC mice infected with ovalbumin-expressing Listeria monocytogenes (LM-OVA) showed reduced CD8 + T cell responses ( Fig. 1g and Extended Data Fig. 4e, f) . Furthermore, following adoptive transfer of OVA-reactive CD8 + T cells (OT-I) and immunization with OVA, proliferation of OT-I cells was greatly impaired in Mst1/2 ΔDC mice ( Fig. 1h and Extended Data Fig. 4g ). Together, these data show that Mst1/2 signalling in DCs is required to orchestrate CD8 + T cell-mediated immune responses in vivo.
Mst1/2 ΔDC mice contained normal percentages of splenic conventional DCs (cDCs) and plasmacytoid DCs (pDCs) (Extended Data Fig. 5a ). Within cDCs, the percentage and number of CD8α
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DCs increased and those of CD8α
− DCs decreased (Extended Data  Fig. 5b ). Mst1/2-deficient DCs showed normal expression of multiple surface molecules, except for a slight reduction of PD-L1 on CD8α − DCs (Extended Data Fig. 5c ). Moreover, mixed bone marrow chimaera experiments revealed a cell-intrinsic role of Mst1/2 in DC homeostasis (Extended Data Fig. 5d-f) . However, loss of Mst1 or Mst2 alone, or deletion of Lats1/2 or Yap/Taz, did not affect DC homeostasis (Extended Data Fig. 6a-c) . Therefore, Mst1/2 control CD8α + DC homeostasis independently of the classical Hippo pathway.
We hypothesized that a selective functional defect of CD8α + DCs in Mst1/2 ΔDC mice accounts for the altered CD8 + T cell homeostasis and activation. The T cell compartment in mice lacking Batf3, whose deletion selectively ablates CD8α + DCs 10 , largely phenocopied those in Mst1/2 ΔDC mice, with reduced effector/memory T cell population and reduced IFNγ expression in CD8 + T cells (Fig. 2a, b) . Additionally, these parameters were comparable between Mst1/2-sufficient and Mst1/2-deficient mice in the Batf3 −/− background (Fig. 2a, b) . We generated Batf3 −/− :Mst1/2 ΔDC mixed bone marrow chimaeras, following an established strategy 11 , to restrict Mst1/2 deficiency to CD8α + DCs only, and found that the chimaeras were impaired in supporting OT-I CD8 + T-cell priming to the same extent as Mst1/2 ΔDC complete chimaeras, indicating a selective defect in CD8α + DCs lacking Mst1/2 ( Fig. 2c and Extended Data Fig. 7a ). To further test this notion, we transferred OT-I T cells into mice deficient in β 2 -microglobulin and thus MHC-I, and immunized these mice with OVA-pulsed CD8α + or CD8α − DCs. Mst1/2-deficient CD8α + DCs induced significantly weaker proliferation of OT-I T cells than wild-type counterparts, whereas wild-type and Mst1/2-deficient CD8α − DCs had comparable function (Extended Data Fig. 7b ). Finally, in an in vivo cross-presentation assay, IFNγ production from endogenous antigen-specific CD8
+ T cells was significantly reduced in Mst1/2 ΔDC mice (Fig. 2d) . Of note, Mst1/2-deficient DCs had no defects in antigen uptake or cell survival (Extended Data Fig. 7c-f) .
Therefore, Mst1/2 are required for in vivo cross-presentation ability of CD8α + DCs. In vitro, Mst1/2-deficient CD8α + DCs showed a profound defect in mediating OT-I T cell proliferation in response to OVA protein, and to a lesser extent, OVA(257-264) peptide (Fig. 2e) , whereas wildtype and Mst1/2-deficient CD8α − DCs had comparable function (Fig. 2e) . Similar phenotypes were observed for IL-2 secretion from OT-I T cells (Fig. 2f) . By contrast, either CD8α + or CD8α − DCs from Mst1/2 ΔDC mice were equivalent to wild-type counterparts in priming proliferation of OVA-specific CD4 + (OT-II) T cells (Extended Data  Fig. 7g ). Mst1/2 deficiency also impaired the CD8 + T cell-priming function of FLT3L-cultured CD24 high bone marrow-derived dendritic cells (BMDCs), which are functionally equivalent to splenic CD8α
+
DCs
12 , but not that of CD24 low cells or GM-CSF-derived BMDCs (Extended Data Fig. 7h-j) . Moreover, CD8α
+ DCs treated with a specific Mst1/2 inhibitor were defective in priming of CD8 + T cells (Extended Data Fig. 7k ). Therefore, Mst1/2 selectively program CD8α + DC functions to prime CD8 + T cells. However, Lats1/2 or Yap/Taz deficiency did not affect the T cell-priming function of CD8α + DCs or their responsiveness to Mst1/2 inhibition (Extended Data Fig. 7l, m) , further establishing a role of Mst1/2 in non-canonical Hippo signalling.
Metabolic reprogramming is associated with DC development and activation 3, 4 , but the metabolic requirements of different DC subsets are poorly defined. Our proteomics profiling revealed a significant enrichment of metabolic pathways in CD8α + DCs (Extended Data  Fig. 8a ). Consistent with these results, CD8α
+ DCs showed much higher oxygen consumption rate (OCR), extracellular acidification rate (ECAR), mitochondrial mass and membrane potential than CD8α − DCs ( Fig. 3a and Extended Data Fig. 8b, c) Letter reSeArCH ability to prime OT-I T cells, whereas these inhibitors had only modest effects on CD8α − DCs (Extended Data Fig. 8d ). Also, deficiency of the metabolic regulator mTOR dampened the CD8 + T cell-priming function of CD8α + DCs (Extended Data Fig. 8e ). Therefore, CD8α
+ DCs have elevated metabolic activities relative to CD8α − DCs, which contribute to their functional capacity.
Furthermore, OCR and ECAR were drastically and selectively reduced in Mst1/2-deficient CD8α + DCs (Fig. 3b) . Since the mitochondrion is the main organelle for oxidative phosphorylation, we measured the structural integrity of mitochondria. Mst1/2-deficient CD8α + DCs had enlarged mitochondria (Fig. 3c ) and abnormal mitochondrial mass and membrane potential (Extended Data Fig. 8f ). Transmission electron microscopy showed that Mst1/2-deficient CD8α + DCs exhibited increased mitochondrial size, but the mitochondrial cristae, which are required for efficient oxidative phosphorylation 13, 14 , were markedly disorganized (Fig. 3d) . By contrast, mitochondrial homeostasis and structure were less affected by Mst1/2 deficiency in CD8α − DCs (Extended Data Fig. 8f, g ). Consistent with the role of mitochondrial cristae in the assembly and stability of respiratory chain complexes 13 , NDUFB8 and MT-CO1, components of respiratory chain complexes I and IV respectively, showed impaired expression in Mst1/2-deficient CD8α + DCs (Extended Data Fig. 8h ). Collectively, Mst1 and Mst2 orchestrate the metabolic activities and mitochondrial integrity of CD8α + DCs. We investigated the molecular basis underlying mitochondrial functions in CD8α + DCs. We noted that Lats1/2-deficient DCs had normal mitochondrial profiles (Extended Data Fig. 8i ). Additionally, mTORC1 activity and c-Myc expression were unaltered by Mst1/2 deficiency (Extended Data Fig. 8j ), and expression of respiratory chain proteins was normal in mTOR-deficient DCs (Extended Data Fig. 8k ). Given the regulation of mitochondrial morphology by fission and fusion processes (mitochondrial dynamics) and the link to oxidative + DCs, n = 3 for Mst1/2-deficient CD8α
+ DCs, n = 6 per genotype for CD8α − DCs), and basal ECAR (n = 9 per genotype for CD8α + DCs, n = 18 for wild-type CD8α , and reduced phosphorylation of the fission protein DRP1 at Ser637, which is mediated by protein kinase A (PKA) to inhibit mitochondrial fission 15 (Fig. 3e) . Moreover, Mst1 interacted with PKA in CD8α + DCs (Fig. 3f) . Thus, in line with the disorganized cristae, Mst1/2-deficient CD8α + DCs have decreased mitochondrial fusion and/or excessive fission. Moreover, treatment of CD8α + DCs with mdivi-1 (a mitochondrial fission inhibitor) and M1 (a mitochondrial fusion promoter) 14 slightly enhanced the function of wild-type DCs, and notably, partially restored the ability of Mst1/2-deficient CD8α + DCs to prime CD8 + T cells (Fig. 3g ). These results show that Mst1/2-dependent mitochondrial dynamics contribute to CD8α + DC function. To identify additional mechanisms that regulate CD8α
+ DC function, we compared gene expression profiles of CD8α + or CD8α -DCs from wild-type and Mst1/2 ΔDC mice using gene-set enrichment analysis (GSEA). The majority of the pathways that were significantly upregulated owing to Mst1/2 deficiency were common to both CD8α + and CD8α − DCs ( Fig. 4a and Extended Data Fig. 9a, b) . By contrast, 18 pathways were significantly downregulated in Mst1/2-deficient CD8α + DCs, whereas none were significantly downregulated in CD8α − DCs ( Fig. 4a and Extended Data Fig. 9c ). IL-12 signalling was the most significantly downregulated gene set in Mst1/2-deficient CD8α + DCs ( Fig. 4b and Extended Data Fig. 9c ). Il12b (encoding IL-12 p40) expression was much higher in wild-type CD8α + DCs than in CD8α − DCs (Extended Data Fig. 9d ), but this expression was considerably dampened by Mst1/2 deficiency ( . 10a ), as seen with Mst1/2-deficient cells. Notably, adding exogenous IL-12 to Mst1/2-deficient CD8α + DCs in vitro rescued, albeit incompletely, their ability to induce OT-I T cell proliferation (Fig. 4d) , and IL-12 treatment in vivo promoted proliferation and CD44 upregulation in OT-I T cells in Mst1/2 ΔDC mice (Fig. 4e) . Therefore, Mst1/2-mediated IL-12 expression contributes to CD8α + DC function in mediating CD8 + T cell homeostasis and priming. How do Mst1 and Mst2 regulate IL-12 expression? Mst1/2-deficient CD8α + DCs exhibited reduced expression of NF-κB2 and RelB, which are involved in the non-canonical NF-κB pathway 17 (Fig. 4b , f and Extended Data Fig. 10b) . A critical mediator of this pathway is NF-κB-inducing kinase (NIK), which functions in DCs to drive IL-12 production and CD8 + T-cell priming 18 . Ectopic expression of constitutively active NIK(Δ78-84) 19 in FLT3L-cultured BMDCs promoted NF-κB2 and RelB expression in wild-type CD24 high BMDCs (Extended Data Fig. 10c) , and largely rescued the impaired expression of Il12b in Mst1/2-deficient cells (Fig. 4g) . Moreover, expression of NIK(Δ78-84) corrected the abnormal mitochondrial membrane potential of Mst1/2-deficient CD24
high BMDCs (Extended Data Fig. 10d ) and increased the ability of these cells to prime CD8 + T cells (Extended Data  Fig. 10e) . Further, Traf3, a key regulator of non-canonical NF-κB-NIK signalling 17 , interacted with Mst1 in CD8α + DCs (Extended Data Fig. 10f ), although Traf3 expression was unaltered by Mst1/2 deficiency (Extended Data Fig. 10g ). Collectively, Mst1 and Mst2 promote the non-canonical NF-κB pathway for IL-12 production and CD8α + DC function.
Given the roles of Mst1/2 in mitochondrial metabolism and IL-12 signalling, we examined whether mitochondrial metabolism is required for IL-12 production. Treatment of CD8α + DCs with metformin or oligomycin increased IL-12 expression (Extended Data Fig. 10h) . Also, CD8α
+ DCs treated with exogenous IL-12 or deficient in IL-12 had 
per genotype). d, Thymidine incorporation of OT-I T cells cultured with CD8α
+ DCs pulsed with OVA protein or OVA(257-264) peptide with or without IL-12 (left, n = 8 from three wild-type mice, n = 9 from three Mst1/2 ∆DC mice; right, n = 7 from three wild-type mice, n = 9 from three Mst1/2 ∆DC mice). The numbers above the graph are the relative ratios of wild-type versus Mst1/2 ∆DC DC groups. e, CFSE dilution (top) and CD62L/CD44 expression (bottom) of transferred OT-I T cells in OVA-immunized mice. f, NF-κB2 (p100) and RelB expression in DCs. g, Relative Il12b expression in wild-type or Mst1/2-deficient CD24 high FLT3L-derived BMDCs transduced with control or NIK(∆78-84) virus (n = 4 mice per group). Data are shown as mean and s.e.m. NS, not significant; *P < 0.05, **P < 0.01; two-tailed unpaired Student's t-test in c, g. Data summarize two (c-f) or three (g) independent experiments.
Letter reSeArCH normal mitochondrial profiles (Extended Data Fig. 10i, j) . However, NIK-deficient CD8α + DCs had abnormal mitochondrial membrane potential and mass (Extended Data Fig. 10k ). Hence, mitochondrial profiles and IL-12 expression are largely discrete events that are coordinately regulated by Mst1/2, although defective non-canonical NF-κB signalling can alter mitochondrial homeostasis.
We explored regulation of Mst1/2 signalling in CD8α + DCs. FLT3L, which promotes DC development and expansion 1 , activated Mst1/2 and downstream signalling in CD8α + DCs (Extended Data Fig. 10l ). Additionally, Mst1/2 deficiency impaired FLT3L-induced expansion of CD8α + DCs (Extended Data Fig. 10m) , indicating a role of Mst1/2 in mediating FLT3L function. Next, we determined whether our findings in the mouse system were reflected in human cells. Mst1/2 inhibition altered mitochondrial mass and impaired IL-12 expression in human CD141
+ DCs (Extended Data Fig. 10n, o) , which are functionally equivalent to murine CD8α + DCs 20 . Therefore, Mst1/2 activity represents an evolutionarily conserved mechanism that regulates DC function.
By integrating a systems biology approach with experimental investigation, our work identifies Mst1/2 as crucial and selective regulators of CD8α
+ DC function and metabolism. Our NetBID algorithm has demonstrated its advantage over conventional methods by successfully identifying 'hidden' kinase drivers from high-throughput profiles, an approach with the potential to be extended to other drivers and biological questions. Mechanistically, we define a non-canonical Hippo signalling pathway (Mst1/2-dependent but Lats1/2-and Yap/ Taz-independent) that coordinates mitochondrial activity and noncanonical NF-κB and cytokine signalling in CD8α + DCs (Extended Data Fig. 10p ). These results highlight that the metabolic state and mitochondrial activity of DC subsets support their functional capacity, and point to a previously unappreciated mechanism that orchestrates DC subset function. Strategies that modulate the activities of DC subset-specific Mst1/2 signalling and metabolic regulation represent attractive means of therapeutic intervention against cancer and immune-mediated diseases.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0177-0. . Sorted DCs were treated with vehicle or 1 μM Mst1/2 inhibitor (XMU-MP-1) 25 (Selleckchem) for 4 h, and RNA was extracted for reverse transcription and real-time PCR using SYBR Green (Thermo Fisher Scientific). The sequences for human IL-12 p40 primers were as follows: forward primer, GACATTCTGCGTTCAGGTCCAG; reverse primer, CATTTTTGCGGCAGATGACCGTG. For mitochondrial mass analysis, DCs were treated with vehicle or 1.5 μM Mst1/2 inhibitor (XMU-MP1) 25 for 4 h at 37 °C and Mitotracker staining was performed according to the manufacturer's instructions (Invitrogen). All human studies were in compliance with the Declaration of Helsinki. Blood donors were recruited by the Blood Donor Center at St. Jude Children's Research Hospital. Blood donors provided written consent for their blood products not used in transfusions to be used for research. This consent form has been reviewed and approved by the Institutional Review Board at St. Jude Children's Research Hospital. In vitro bone marrow-derived DCs. Bone marrow cells were flushed from mouse tibias and femurs, and red blood cells were lysed using ACK lysis buffer. For FLT3L-BMDCs, bone marrow cells were cultured in RPMI-1640 medium (plus β-mercaptoethanol) containing 10% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin (complete RPMI-1640 medium) and mouse FLT3L (200 ng/ml) for 9.5-11.5 days. For GM-CSF-BMDCs, bone marrow cells were cultured in complete RPMI-1640 medium and mouse GM-CSF (20 ng/ml) and IL-4 (5 ng/ml) for 7.5-9.5 days. Loosely adherent cells were collected for analysis. Antigen challenge. Antigen-specific T cells from OT-I (CD45.1 + ; 1 × 10 6 ) TCR-transgenic mice were sorted and labelled with CFSE, and transferred into wild-type and Mst1/2 ΔDC mice intravenously. Twenty-four hours later, the mice were injected intravenously with 30 μg OVA (low Endo, Worthington) . Three days after OVA immunization, spleen and peripheral lymph nodes were isolated for further analyses. For in vivo IL-12 treatment, 2 μg IL-12 per mouse was injected intraperitoneally each day for three consecutive days starting from 24 h after OT-I CD8 + T cell transfer.
Tumour model. MC38 colon adenocarcinoma cells were cultured in DMEM supplemented with 10% (vol/vol) FBS and 1% (vol/vol) penicillin-streptomycin. Wild-type and Mst1/2 ΔDC -derived bone marrow chimaera mice were injected subcutaneously with 5 × 10 5 MC38 cells in the right flank. Tumours were measured regularly with calipers. Tumour volumes were calculated using the formula: length × width × width × π/6. To prepare tumour-infiltrating lymphocytes, tumour tissues were excised, minced and digested with 0.5 mg/ml Collagenase IV (Roche) +200 U/ml DNase I (Sigma) for 1 h at 37 °C. Tumour-infiltrating lymphocytes were then isolated by density-gradient centrifugation over Percoll (Life Technologies). Listeria monocytogenes-OVA infection model. Mice were infected intravenously with 3 × 10 4 colony-forming units (CFU) of L. monocytogenes expressing chicken ovalbumin (LM-OVA), and were bled at the indicated days post infection to collect cells for analysis. Flow cytometry. Flow cytometry was performed as described previously 23 
Antigen presentation assays. For in vitro assays, CD8α
+ and CD8α − DCs were sorted from spleen, pulsed with 500 μg/ml OVA, 250 pg/ml OVA(257-264) or 3 μg/ml OVA(323-339) peptide for 1 h, then washed twice and cultured with naive CD4
+ T cells from OT-II mice or naive CD8 + T cells from OT-I mice for three days. Thymidine was added to the culture 7-8 h before cells were collected to measure proliferation. Where indicated, DCs were pre-treated with 0.2 μM M1 26 + 0.1 μM mdivi-1 27 for 4 h before co-culture with T cells. For in vivo assays by DC transfer method, FLT3L (10 μg/ml in 100 μl PBS) was injected subcutaneously once daily into wild-type or Mst1/2 ΔDC mice for nine consecutive days 28 , and then CD8α + and CD8α − DCs were sorted and pulsed with 20 mg/ml OVA for 1.5 h, washed and intravenously injected into Β2m −/− mice that had received CFSE-labelled CD8 + OT-I (CD45.1 + ) T cells the day before. Β2m −/− mice were killed three days after DC immunization, and CFSE dilution of CD8 + OT-I T cells was examined by flow cytometry. In vivo cross-presentation assay using tetramer detection methods was performed according to previous reports 29, 30 . In brief, Β2m −/− splenocytes were osmotically loaded with 10 mg/ml OVA (Worthington Biochemical Corporation), washed, irradiated at 13.5 Gy, and 1.5 × 10 7 cells were intravenously injected into mice. After eight days, spleens were harvested and analysed by H-2K b -OVA tetrameter staining. RNA and immunoblot analyses. Real-time PCR analysis was performed as previously described with primers and probe sets from Applied Biosystems 31 . Immunoblots were performed and quantified as described previously 12 , using the following antibodies: NF-κB2 (#4882), RelB (#4954), p-Mst1/2 (#3681), p-Yap (Ser127) (D9W2I), Lats1 (C66B5), Mst1 (D8B9Q), Mst2 (#3952), Actin (8H10D10), p-DRP1 (Ser637) (#4867), p-S6 (2F9), c-Myc (#9402 s) (all from Cell Signaling Technology), OPA1 (NB110-55290SS, Novus Biologicals) and MitoProfile Total OXPHOS (oxidative phosphorylation) Rodent WB Antibody Cocktail (MS604, MitoSciences).
Co-immunoprecipitation of Mst1-associated complexes from splenic CD8α
+
DCs. Wild-type splenic CD8α
+ DCs (after in vivo FLT3L expansion to obtain sufficient cells) were lysed in lysis buffer (25 mM Tris-HCl pH 7.5, 130 mM NaCl, 20 mM NaF, 1% Triton X-100, 2 mM EDTA) and pre-cleaned by incubating with 40 μl Protein A/G beads (50% vol/vol slurry, Santa Cruz sc-2003) for 2 h. The Mst1-associated complexes were immunoprecipitated with Mst1 antibody (EP1465Y, Abcam), which had pre-coupled with Protein A/G Sepharose beads for 4 h at 4 °C. After three washes with the lysis buffer, the immune complexes were analysed by immunoblotting with PKA Cα/β (#515741, R&D), Traf3 (#4729, Cell Signaling Technology), and Mst1 antibodies. Super-resolution fluorescence microscopy. Stochastic optical reconstruction microscopy (STORM) was performed as described 32 . In brief, sorted DC subsets were seeded onto Poly-l-Lysine coated chamber slides (Ibidi USA) and allowed to settle for 30 min before fixation with 4% paraformaldehyde followed by treatment with sodium borohydride to quench free reactive groups. Cells were permeabilized for 3 min in buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl) containing 0.1% Triton X-100 before blocking in buffer containing 2% BSA and 0.05% Tween-20. Samples were incubated overnight in TBS buffer containing BSA and anti-Tom20 (Santa Cruz; sc-11415, 1:500 dilution) and subsequently detected with CF647 labelled secondary antibody (Biotium). Three-dimensional STORM image acquisition was performed with an N-STORM system (Nikon Instruments) comprised of a 100× 1.49NA TIRF objective and an astigmatic lens inserted into the light path, before collection using an iXon DU897 ultra EMCCD camera with frame rate of 109 frames per second and EM gain of 17 mHz at 16 bit, as previously described 32 . Images were processed using algorithms as previously described 33 and incorporated into Elements imaging software (Nikon Instruments). Transmission electron microscopy. Sorted DC subsets were pelleted by centrifugation and fixed in 0.1 M sodium cacodylate buffer, pH 7.4, containing 2.5% glutaraldehyde and 2% paraformaldehyde. Samples were post-fixed in 2% osmium tetroxide in 0.1 M cacodylate buffer with 0.15% potassium ferrocyanide, followed by dehydration to propylene oxide and embedding in epoxy resin. TEM images of ultrathin (80 nm) sections were acquired using a FEI Tecnai 20 200 KV FEG electron microscope. Metabolic assays. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured in Seahorse XF media under basal conditions and in response to 1 μM oligomycin, 1.5 μM fluoro-carbonyl cyanide phenylhydrazone (FCCP) and 500 nM rotenone using an XF96 Extracellular Flux Analyzer (EFA) (Seahorse Bioscience).
Whole and phosphoproteome profiling by multiplex TMT-LC/LC-MS/MS.
Protein extraction, digestion, labelling and pooling. Whole proteome and phosphoproteome profiling was performed as described 34 .
CD8α
+ and CD8α − DCs were sorted from wild-type spleen as described above. Cells were washed twice with ice-cold PBS and cell pellets from six samples (n = 3 per cell type) were lysed in fresh lysis buffer (50 mM HEPES, pH 8.5, 8 M urea and 0.5% sodium deoxycholate). The protein concentration of lysate was quantified by BCA protein assay (Thermo Fisher Scientific). Proteins (100 μg) from each sample were loaded and run on a 10% SDS-PAGE gel until all samples were inside the gel. The gel was stained and each sample was sliced and further chopped into 1 mm 3 pieces. After gel detaining, the proteins were reduced with 5 mM dithiothreitol at 37 °C for 30 min and alkylated with 10 mM iodoacetamide at room temperature in the dark for 30 min. Proteins were then digested in-gel with trypsin in 50 mM HEPES overnight at 37 °C with a protein to trypsin ratio (w/w) of 50:1. Peptides for each sample were extracted, dried and labelled with 6-plex tandem mass tag (TMT, Thermo Fisher Scientific) reagents following the manufacturer's instructions. Finally, the TMT-labelled samples were equally mixed. Offline basic pH reverse phase liquid chromatography. The mixture of the 6 TMTlabelled samples was desalted, dried and solubilized in 60 μl buffer A (10 mM ammonium formate, pH 8) and separated on an XBridge C18 column (3.5-μm particle size, 4.6 mm × 25 cm, Waters) into 44 fractions with an 88-min gradient from 15% to 45% buffer B (95% acetonitrile, 10 mM ammonium formate, pH 8, flow rate of 0.4 ml/min). Each fraction was dried for whole-proteome analysis. Acidic pH reverse phase liquid chromatography coupled with tandem mass spectrometry. The analysis was performed based on our optimized platform 35 . For whole proteome analysis, the dried peptides were reconstituted in 5% formic acid, loaded on a reverse phase column (75 μm × 30 cm, 1.9 μm C18 resin (Dr. Maisch, Germany)) interfaced with a Q-Exactive HF mass spectrometer (ThermoFisher Scientific). Peptides were eluted by 12-36% buffer B gradient in 2.5 h (buffer A: 0.2% formic acid, 3% DMSO; buffer B: buffer A plus 67% acetonitrile, flow rate of 0.25 μl/min). The column was heated at 65 °C by a butterfly portfolio heater (Phoenix S&T) to reduce back pressure. The mass spectrometer was operated in data-dependent mode with a survey scan in Orbitrap (60,000 resolution, 1 × 10 6 AGC target and 50 ms maximal ion time) and 20 tandem mass spectrometry (MS/ MS) high-resolution scans (60,000 resolution, 1 × 10 5 AGC target, 105 ms maximal ion time, HCD, 35 normalized collision energy, 1.0 m/z isolation window, and 20 s dynamic exclusion). Proteomics data analysis. The analysis was performed by our in-house JUMP search engine which has been used for data processing in previous publications 34 . In brief, acquired MS/MS raw files were converted into mzXML format and searched by the JUMP algorithm against a composite target/decoy database to estimate FDR. The target protein database was downloaded from the Uniprot mouse database (52,490 protein entries) and the decoy protein database was generated by reversing all target protein sequences. Searches were performed with 10 ppm mass tolerance for both precursor ions and product ions, fully tryptic restriction, two maximal missed cleavages and the assignment of a, b and y ions. TMT tags on lysine residues and peptide N termini (+229.162932 Da) and carbamidomethylation of cysteine residues (+57.021 Da) were used for static modifications and oxidation of methionine residues (+15.99492 Da) were used for dynamic modification. The assigned peptides were filtered by mass accuracy, minimal peptide length, matching scores, charge state and trypticity to reduce protein false discovery rate (FDR) to below 1%. TMT-based protein quantification. The analysis was performed using in-house JUMP software suite as previously reported 34 . In brief, TMT reporter ion intensities of each peptide spectrum match (PSM) were extracted and PSMs with very low intensity were removed. The raw intensities were then corrected based on isotopic distribution of each labelling reagent and loading bias. The mean-centred intensities across samples were calculated and protein relative intensities were derived by averaging related PSMs. Finally, protein absolute intensities were determined by multiplying the relative intensities by the grand-mean of three most highly abundant PSMs. Gene expression profiling and bioinformatics analysis. Total, CD8α
+ and CD8α − DCs (n = 4 per genotype) were isolated from spleen as described above. RNA was obtained with an RNeasy Micro Kit according to the manufacturer's instructions (Qiagen). RNA samples were then analysed with the Mouse Gene 2.0 ST Signals array. Differentially expressed transcripts were identified by ANOVA (Partek Genomics Suite version 6.5), and the Benjamini-Hochberg method was used to estimate the FDR as described 36 . GSEA was performed as described 36 . Batch effect removal of combined gene expression data. We combined multiple batches of microarray gene expression profiles of total (n = 15), CD8α + (n = 4) and CD8α
− (n = 4) DCs, and removed batch effects by using 'removeBatchEffect' function in limma 37 . A principal component analysis (PCA) plot of the corrected microarray profiles (Extended Data Fig. 1a ) indicated significant differences among the three groups of DCs. NetBID algorithm. We and others have demonstrated that important signalling proteins might not change at individual mRNA expression levels 6, 7, 38 , and existing network-based methods 6,7,38-41 to infer master regulators are largely based on transcriptomics data only. In order to identify the true underlying signalling drivers of CD8α + DCs in an unbiased and systematic manner, we developed the data-driven network-based Bayesian inference of drivers (NetBID) algorithm by integrating transcriptomics (mRNA), whole proteomics (wProtein) and phosphoproteomics (pProtein) data. First, we collected a cohort of baseline transcriptomic profiles of total DCs and reverse engineered a DC-specific signalling interactome or DCI, using an improved version of ARACNE 42 , an information theory-based algorithm for regulatory network inference. The data-driven DCI resulted in 20,846 nodes and 660,929 edges. Second, we focused on kinase signalling networks in DCI and calculated activity scores of all kinase candidates (n = 289 present in all three platforms) in mRNA, wProtein and pProtein profiles of CD8α + and CD8α − DCs using z-normalization and z-statistic 43, 44 . We then used a Bayesian linear modelling approach 45 to identify differentially activated kinases by comparing profiles of CD8α
+ with CD8α − DCs at mRNA, wProtein and pProtein levels separately. Finally, we integrated three differential activity scores using the unsigned Stouffer's method 46 and identified 36 kinase drivers that were differentially activated between CD8α + and CD8α − DCs at mRNA, wProtein and pProtein levels with cutoffs of FDR at 0.01 and network size at 50. Remarkably, most of the 36 kinases themselves showed little change between CD8α + and CD8α − DCs or even reduced in CD8α
+ DCs, and would likely be missed by conventional differential expression approaches. Mst1 and a few other Hippo kinases were confirmed to have higher activity in CD8α + DCs, indicating the power of NetBID to identify 'hidden' drivers. Signalling pathway enrichment of identified kinase drivers. To identify any known signalling pathways enriched by the 36 NetBID-inferred kinase drivers of CD8α + DCs, we used Fisher's exact test against all pathways with 'signaling' in their names from MSigDB 47 (v6.0). We manually curated the Hippo signalling kinases using the most recent literature 9 as we observed a number of known Hippo kinases present in the 36 kinase driver list, which turned out to be more significant than all existing signalling pathways in the database. This also suggests the limitation of knowledge-based pathway databases. Retroviral generation and transduction of FLT3L-BMDCs. Retroviruses were produced by transfection of Plat-E cells with an empty pCLXSN (GFP) vector or the same vector encoding NIK(Δ78-84) mutant, along with pCL-Eco packaging vectors. NIK(Δ78-84) lacks a Traf3-binding motif and is potent in activating the non-canonical NF-κB pathway 19 . Bone marrow cells were cultured with FLT3L for one day; cells were then 'spin-infected' (2,500 r.p.m.) for 180 min at 30 °C. After spinning, fresh DC medium containing FLT3L was added to the cells and cells were cultured according to the standard procedure described above. Statistical analysis for small-scale immunological experiments. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment. Data were analysed using Prism 6 software (GraphPad) by two-tailed Student's t-test or one-way or two-way ANOVA as noted in figure legends. P < 0.05 was considered significant. Data are presented as mean ± s.e.m. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.
Letter reSeArCH
Software and data availability. 
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Experimental design 1. Sample size
Describe how sample size was determined. Sample size was selected to maximize the chance of uncovering mean difference which is also statistically significant.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All the experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not used.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
